A division of Alnylam Pharmaceuticals.

Importantly, we now have demonstrated the use of RNAi technology with CHO cells grown in 40 liter bioreactors, with results comparable to what we seen in one and three liter cell cultures,’ stated Stuart Pollard, Ph.D., Vice President, Scientific and Business Strategy of Alnylam. ‘Our efforts in Alnylam Biotherapeutics are continuing to advance at an extremely rapid pace, clearly demonstrating the potential of RNAi technology to broadly and significantly improve the quality, quantity, and features of biotherapeutics.’ Studies had been performed using Alnylam’s proprietary NDLs, compared with available lipids commercially, to provide siRNAs into Chinese Hamster Ovary cells.Professor Jamrozik’s first passions in tobacco control began as a medical intern at the Royal Hobart Medical center during the past due 1970s, where he became acutely alert to the dangerous consequences of smoking cigarettes and the effect it had been having on individuals. It occurred to me that there was a lot of absurdity in patients utilizing their dying breaths to smoke one last cigarette, or admitting a patient to medical center for his second heart attack because no-one experienced convinced him to stop smoking to begin with, Professor Jamrozik says.

Other Posts From "treatments":

Related Posts